Bacterial Coinfection Among Coronavirus Disease 2019 Patient Groups: An Updated Systematic Review and Meta-Analysis Publisher



Soltani S^{1, 2} ; Faramarzi S³ ; Zandi M^{1, 2} ; Shahbahrami R² ; Jafarpour A^{2, 4} ; Akhavan Rezayat S⁵ ; Pakzad I⁶ ; Abdi F⁷ ; Malekifar P⁸ ; Pakzad R^{9, 10} Show Affiliations
Source: New Microbes and New Infections Published:2021

Abstract

The pandemic of severe acute respiratory syndrome coronavirus 2 raised the attention towards bacterial coinfection and its role in coronavirus disease 2019 (COVID-19) disease. This study aims to systematically review and identify the pooled prevalence of bacterial coinfection in the related articles. A comprehensive search was conducted in international databases, including MEDLINE, Scopus, Web of Science, and Embase, to identify the articles on the prevalence of bacterial coinfections in COIVD-19 patients from 1 December 2019 until 30 December 2020. All observational epidemiological studies that evaluated the prevalence of bacterial coinfections in patients with COVID-19 were included without any restriction. Forty-two studies including a total sample size of 54,695 were included in the analysis. The pooled estimate for the prevalence of bacterial coinfections was 20.97% (95% CI: 15.95–26.46), and the pooled prevalence of bacterial coinfections was 5.20% (95% CI: 2.39–8.91) for respiratory subtype and 4.79% (95% CI: 0.11–14.61) for the gastrointestinal subtype. The pooled prevalence for Eastern Mediterranean Regional Office and South-East Asia Regional Office was 100% (95% CI: 82.35–100.00) and 2.61% (95% CI: 1.74–3.62). This rate of coinfection poses a great danger towards patients, especially those in critical condition. Although there are multiple complications and adverse effects related to extensive use of antibiotics to treat patients with COVID-19, it seems there is no other option except applying them, and it needs to be done carefully. © 2021 The Authors